Discovery of 4-((2 <i>S</i> ,4 <i>S</i> )-4-Ethoxy-1-((5-methoxy-7-methyl-1 <i>H</i> -indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Christopher M. Adams, Chun Zhang et al.|Journal of Medicinal Chemistry|2020Cited by 61
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction InhibitorsHolger Sellner, Nicolas Soldermann|ChemMedChem|2023Cited by 23
Complement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degenerationMaura Crowley, Sha-Mei Liao, Donita Garland et al.|Human Molecular Genetics|2022Cited by 18
Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indoleNello Mainolfi, Bruce Jaffee, Takashi Ehara et al.|Unknown|2019Cited by 0